GlassScriptPhysician profile
Brian D Haas
NPI 1568490084
$6,909.89
in general payments reported to CMS, 2019-2025
34 companies · $582 in 2025
The $582 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,787 · 2020: $731 · 2021: $1,357 · 2022: $564 · 2023: $546 · 2024: $342 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,470.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,954.78 | 2019-2025 | Tecnis Iol, Tecnis Iol |
| Alcon Vision LLC | $1,738.98 | 2019-2025 | Argos, Unity, Centurion |
| Merz North America, INC. | $512.88 | 2019-2025 | Xeomin |
| Horizon Therapeutics Plc | $509.85 | 2019-2023 | Tepezza |
| Sight Sciences, INC. | $389.75 | 2021-2025 | Tearcare System, Sion Surgical Instrument, Omni Surgical System |
| Allergan, INC. | $170.02 | 2019-2021 | |
| Ivantis, INC | $149.91 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $133.18 | 2019-2021 | |
| Galderma Laboratories, L.P. | $124.30 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $114.70 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Kala Pharmaceuticals, INC. | $90.52 | 2021-2022 | |
| Rxsight INC | $86.18 | 2020-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Amgen INC. | $85.73 | 2024-2025 | Tepezza |
| Carl Zeiss Meditec, INC. | $72.35 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $71.62 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $70.08 | 2024-2025 | Idosetr, Idose |
| Tarsus Pharmaceuticals, INC. | $66.91 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $55.09 | 2022-2023 | Tyrvaya |
| Dompe US, INC. | $45.78 | 2024 | Oxervate |
| Novartis Pharmaceuticals Corporation | $43.78 | 2019-2022 | |
| Harrow Eye, LLC | $43.58 | 2024 | Vevye |
| Eyevance Pharmaceuticals LLC | $43.22 | 2021 | |
| Ocular Therapeutix, INC. | $42.02 | 2023 | Dextenza |
| Lumibird Medical INC. | $41.69 | 2025 | |
| Biotissue Holdings INC. | $39.99 | 2020-2024 | |
| Sun Pharmaceutical Industries INC. | $35.13 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $29.85 | 2023 | Libtayo |
| Eyepoint US, INC. | $24.92 | 2020 | |
| Shire North American Group INC | $24.13 | 2019 | |
| Revance Therapeutics, INC. | $21.67 | 2025 | Daxxify |
| Apellis Pharmaceuticals, INC. | $21.17 | 2025 | Syfovre |
| Aerie Pharmaceuticals, INC. | $20.25 | 2019 | |
| Abbvie INC. | $19.20 | 2022 | |
| Ani Pharmaceuticals, INC. | $16.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Haas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.